| Name | Hemogenyx Pharmaceuticals |
|---|---|
| Epic | HEMO |
| Isin | GB00BYX3WZ24 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 376.95p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £13.59 | Debt ratio | n/a |
| Shares in issue | 1,401.82 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | -123 |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | -0.6 | 52-week high / low | 320.00p / 1,582.00p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | Hemogenyx Pharmaceuticals |
|---|---|
| Address | 6th Floor, 60 Gracechurch Street, London, United Kingdom, EC3V 0HR |
| Telephone | |
| Website | http://hemogenyx.com/ |
| Director | Position |
|---|---|
| Dr Vladislav Sandler Ph.D. | CEO |
| Ms Alexis M. Sandler | Non-Executive Director |
| Mr Peter Redmond | Non-Executive Director |
| Sir Marc Feldmann | Non-Executive Chairman |
| Assets £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Reporting date | 31/12/23 | 31/12/22 | 31/12/21 |
| Intangible asssets and goodwill | 0.47 | 0.44 | 0.44 |
| Investments and other non-current assets | n/a | n/a | n/a |
| Total non-current assets | 3.94 | 4.5 | 1.38 |
| Inventory / work in progress | n/a | n/a | n/a |
| Trade and other receivables | 0.92 | 0.06 | 0.3 |
| Cash and equivalents | 1.25 | 2.53 | 6.84 |
| Other current assets and asset held for resale | n/a | n/a | n/a |
| Total of all assets | 6.11 | 7.09 | 8.52 |
| Liabilities £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Short term liabilities | 0.65 | 0.75 | 0.35 |
| Long term liabilities | 2.67 | 3.1 | n/a |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 3.32 | 3.85 | 0.35 |
| Net assets £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Net assets | 2.78 | 3.24 | 8.17 |
| Equity £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Share capital | 11.76 | 9.8 | 9.8 |
| Minority interests | -0.04 | -0.03 | -0.02 |
| Retained earnings | -23.8 | -17.11 | -13.13 |
| Share premium account | 19.94 | 16.81 | 16.81 |
| Total equity | 2.78 | 3.24 | 8.17 |
| Income £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | -6.47 | -4 | -2.7 |
| Pre-tax profit | -6.7 | -3.99 | -5.11 |